Protein immobilization strategy to be applied to the SPR biosensing platform now commercialized by Nicoya Lifesciences.

虽然SPR生物传感器市场几十年来一直由Biacore仪器（GE Healthcare）主导， 几家初创公司最近推出了他们自己负担得起的开放式结构SPR生物传感器。等 Nicoya Lifesciences是一家总部位于滑铁卢（安大略省）的加拿大公司。现在的挑战之一 该公司面临的是为客户提供强大的和通用的协议，以拴系蛋白质或 肽在其生物传感器的表面以定向和稳定的方式，因此使表面多功能 并且可重复使用。 该合作项目之间的理工学院和Nycoya生命科学将包括开发 和测试基于使用从头设计的肽异源二聚化系统的新方案， 在Nicoya SPR生物传感器表面捕获嵌合蛋白。一些生物系统，如 单克隆抗体或与其受体或生长因子结合将作为案例研究。 这个Engage与De Crescenzo教授的实验室合作项目，De Crescenzo教授是该领域的知名专家， 特别方案资源对实现这些目标具有战略意义。该项目将为Nicoya Lifesciences提供 多功能捕获工具将被集成到他们的生物测定产品组合中。这些工具将很容易适应 满足新客户的需求。这些活动也有可能大大改善 因为他们将证明Nicoya仪器对单克隆抗体的适用性 量化市场

While the SPR biosensor market has been dominated for decades by Biacore instruments (GE Healthcare), several startup companies have recently launched their own affordable open-architecture SPR biosensors. Such is the case for Nicoya Lifesciences, a Canadian company based in Waterloo (ON). One of the challenges now faced by the company is to provide their customers with robust and versatile protocols to tether proteins or peptides in an oriented and stable fashion at the surface of their biosensors, hence making the surface versatile and reusable. This collaborative project between École Polytechnique and Nycoya Lifesciences will consist in developing and testing novel protocols based on the use of a de novo designed peptide heterodimerizing system for the capture of chimeric proteins at the surface of Nicoya SPR biosensors. Several biological systems, e.g. monoclonal antibody or binding to their receptors or to growth factors, will serve as case studies. This Engage collaborative project with the laboratory of Prof. De Crescenzo, a renowned expert in the field of SPR, will be strategic to achieve these objectives. This project will provide Nicoya Lifesciences with a versatile capture tool to be integrated in their portfolio of bioassays. These tools will be readily adaptable to address the needs of their new customers. These activities also have the potential to drastically improve the company sales as they will demonstrate the applicability of Nicoya instruments to the monoclonal antibody quantitation market.